ClinicalTrials.gg
CompletedNCT05265247Updated Feb 5, 2024Results posted

Bioequivalence Study of Esomeprazole 20 Milligram (mg) Delayed-Release Capsules in Healthy Adult Participants

A Phase 1 interventional study of Esomeprazole 20 mg Delayed-Release Capsules and Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR) in Gastrointestinal Diseases, sponsored by HALEON. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-05.

Sponsored by HALEON · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Gastrointestinal Diseases with a site in Canada — 4 open to participants now, 12 under way, 3 of them phase 3. Gastrointestinal Diseases · Canada.

Enrollment
24th of 27
61 · median 214
Started
2022
with 2 others
Phase 1
Only one
of the 40
Registered
29th of 40
by date

Among the 40 studies in Gastrointestinal Diseases with a site in Canada, this one is the 24th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2022, is the only one in phase 1, and was the 29th registered.

Gastrointestinal Diseases

549 studies on the registry are indexed under Gastrointestinal Diseases; 102 are open to participants now.

Browse Gastrointestinal Diseases studies →

Open to participants now

4 of the 40 studies in Gastrointestinal Diseases with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 66 Gastrointestinal Diseases studies recruiting now, 30 (45%) set no upper age limit and 23 (35%) stop at 75 or younger; 19 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Gastrointestinal Diseases with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate bioequivalence parameters of esomeprazole capsules 20 mg (test product) vs. esomeprazole capsules 20 mg (reference product) under fasted conditions.

Read the detailed description

This will be a single center, single dose, single-blind, randomized, two-sequence, two-period crossover, bioequivalence study in healthy adult participants with at least a 7-day washout period. The study will consist of an ambulant screening day within 28 days prior to first product administration and two study periods.

03

Conditions studied

  • Gastrointestinal Diseases
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of a personally signed and dated document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • Participant who is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Healthy Participant, which is defined as in general good physical health, as judged by the investigator and no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead (ECG) or clinical laboratory tests.
  • (BMI) of 18.5 to 30.0 Kilogram per square meter (kg/m\^2); and a total body weight Greater than or equal to (>=) 50.0 kg for males and >=45.0 kg for females.
  • Participant with two negative tests (one at screening within 72 hours of admission and one at check on Day-1) for active COVID-19, separated by Greater Than (>) 24 hours.
  • Female participant of and at risk for pregnancy must agree to use a highly effective method of throughout the study and for at least 30 days after the last dose of assigned treatment. Female participants who are not of childbearing potential must meet requirements in the Contraception section of protocol.

Exclusion criteria

Exclusion Criteria:

  • Participant who is an site staff member directly involved in the conduct of the study and his/her family members, site staff member otherwise supervised by the investigator, or participant who is a GSK employee directly involved in the conduct of the study.
  • Participation in other studies involving investigational drug(s) within 30 days prior to study entry and/or during study participation.
  • Acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Pregnant female participant.
  • Breastfeeding female participant.
  • Known or suspected intolerance or or photosensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
  • Diagnosis of long syndrome or QTc > 450 Millisecond (msec) for males and > 470 msec for females.
  • vital sign abnormalities (systolic blood pressure lower than 90 or over 140 Millimeter of mercury (mmHg), diastolic blood pressure lower than 50 or over 90 mmHg, or pulse rate less than 50 or over 100 beats per minute (bpm).
  • A participant unwilling or unable to comply with Lifestyle Considerations described in this protocol.
  • Use of any medication (including over-the-counter medications and herbal remedies) within 2 weeks before first scheduled study drug administration or within less than 10 times the elimination half-life of the respective drug (whichever is longer), or is anticipated to require any concomitant medication during that period or at any time throughout the study. Allowed treatments are:

    • systemic and hormone replacement therapy, as long as female participant is on stable treatment for at least 3 months before first scheduled study drug administration and continues treatment throughout the study;
    • occasional use of acetaminophen (up to 2 g daily).
  • Evidence or history of clinically significant laboratory abnormality, hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease within the last 5 years that may increase the risk associated with study participation.
  • Clinically relevant chronic or acute infectious illnesses or febrile infections within two weeks prior to start of the study.
  • Participant with signs and symptoms suggestive of COVID-19 (i.e. fever, cough, etc)* within 14 days of inpatient admission. *as defined by WHO or local guidance)
  • Participant with known COVID-19 positive contacts in the past 14 days.
  • Any vaccination, including COVID-19 vaccine, within 14 days prior to the first dose.
  • Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance but not limited to any of the following:

    • History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling or gastric banding (note: this is not applicable for minor abdominal surgery without significant tissue resection, e.g., appendectomy and herniorrhaphy);
    • History of inflammatory bowel disease;
    • History or current evidence of renal disease or impaired renal function at screening as indicated by abnormal levels of serum creatinine (> 123 micromole per liter [μmol/L] for males and > 95 μmol/L for females) or blood urea nitrogen (BUN) (>= 12.0 millimoles per liter [mmol/L]) or the presence of clinically significant abnormal urinary constituents (e.g. albuminuria);
    • History or current evidence of ongoing hepatic disease or impaired hepatic function at screening. A candidate will be excluded if more than one of the following lab value deviations are found: 1) (AST) (>= 1.2 [ULN]), alanine transaminase [ALT] (>= 1.2 ULN), 2) gamma-glutamyl transpeptidase (GGT) (>= 1.2 ULN), alkaline phosphatase (ALP) (>= 1.2 ULN), 3) (>= 48 μmol/L for males and >= 30 μmol/L for females) or creatine kinase (CK) (>= 3 ULN). A single deviation from the above values is acceptable and will not exclude the candidate, unless specifically advised by the investigator;
    • Evidence of urinary obstruction or difficulty in voiding at screening;
    • History or clinical evidence at screening of pancreatic injury or pancreatitis.
  • Participant has a history of drug abuse or investigator has evidence of current drug abuse with drug classes that include but are not limited to barbiturates, tricyclic antidepressants, amphetamines, benzodiazepines, cocaine, opiates, cannabis or any other drugs (verified by urine drug screen or other reliable evidence).
  • Evidence, as reported by an alcohol breath testing, for current alcohol abuse or reports a regular average alcohol consumption exceeding 18 g (women) or 35 g (men) of pure alcohol per day, i.e. 1 drink/day for women or 2 drinks/day for men (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of screening.
  • Participant reported regular consumption of > 5 cups of coffee or tea per day (or equivalent consumption of >= 500 mg xanthine per day using other products)
  • Smoker, defined as the use of tobacco or nicotine products during the 3 months prior to screening until admission to the unit or a positive urine cotinine test at screening.
  • A participant who is unwilling to abstain from tobacco or nicotine-containing product use during the study.
  • Participant reports consumption of any drug metabolizing enzyme (e.g. cytochrome P450 [CYP]3A4 or other cytochrome P450 enzymes) inducing or inhibiting aliments, beverages or food supplements (e.g. broccoli, Brussels sprouts, grapefruit, grapefruit juice, star fruit, St. John's Wort etc.) within 2 weeks prior to screening until admission to the unit.
  • Positive results in any of the virology tests for (HIV) antigen and antibody, virus antibody (HCV Ab), surface antigen (HbsAg), and hepatitis B core antibody (HBcAb) ([immunoglobulin G] IgG + immunoglobulin M [IgM]).
  • Performance of unaccustomed strenuous physical exercise (body building, high performance sports) from 2 weeks prior to admission and throughout the entire study.
  • Allergy to skin disinfecting agents, tape, or latex rubber, whenever appropriate substitutions cannot be applied or in the investigator's opinion may pose a risk to the candidate.
  • Any condition not identified in the protocol that in the opinion of the investigator would confound the evaluation and interpretation of the study data or may put the participant at risk
  • Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 milliliter (mL) to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dose.
  • Participant who has previously been enrolled in this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Test Product/Reference Product

    Participants will be randomly assigned to receive Esomeprazole 20 mg delayed-release one capsule once daily as oral administration on day 1 of period 1 and will receive Esomeprazole 20 mg delayed-release one capsule (Nexium 24HR) once daily as oral administration on day 1 of period 2. Participants are instructed to consume the entire amount of ambient temperature water (240 milliliter \[mL\]) along their investigational product. There will be washout period of 7 days between two treatment periods.

    Drug: Esomeprazole 20 mg Delayed-Release Capsules · Drug: Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)

  • Experimental
    Reference Product/Test Products

    Participants will be randomly assigned to receive Esomeprazole 20 mg delayed-release one capsule (Nexium 24HR) once daily as oral administration on day 1 of period 1 and will receive Esomeprazole 20 mg delayed-release one capsule once daily as oral administration on day 1 of period 2. Participants are instructed to consume the entire amount of ambient temperature water (240 milliliter \[mL\]) along their investigational product. There will be washout period of 7 days between two treatment periods.

    Drug: Esomeprazole 20 mg Delayed-Release Capsules · Drug: Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Post Dose Concentration (Cmax)

    Cmax is defined as maximum observed post-dose concentration; obtained without interpolation. Blood samples were collected at the indicated time points for the analysis of Cmax. Pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis.

    Time frame: Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)

  2. Area Under the Plasma Concentration Versus Time Curve Calculated From Time 0 to the Last Measurable Sampling Time Point

    AUC(0-t) is defined as area under the plasma concentration versus time curve calculated from time 0 to the last measurable sampling time point t, computed using the linear trapezoidal rule. Blood samples were collected at the indicated time points for the analysis of AUC0-t. PK parameters were calculated by standard non-compartmental analysis.

    Time frame: Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)

Secondary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve Calculated From Time 0 to Infinity (AUC0-inf)

    AUC(0-inf) is defined as area under the plasma concentration versus time curve calculated from time 0 to infinity. AUC0-inf is equal to (=) AUC0-t plus (+) concentration at the last measurable sampling time point \[C(t)\]/terminal elimination rate constant (λz). Blood samples were collected at the indicated time points for the analysis of AUC0-inf. PK parameters were calculated by standard non-compartmental analysis.

    Time frame: Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)

  2. Percentage of AUC(0-inf) Obtained by Extrapolation (%AUCex)

    %AUCex is defined as percentage of AUC(0-inf) obtained by extrapolation, calculated as (1-\[AUC{0-t}/AUC{0-inf}\]) ×100. Blood samples were collected at the indicated time points for the analysis of %AUCex. PK parameters were calculated by standard non-compartmental analysis.

    Time frame: Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)

  3. Terminal Elimination Rate Constant

    λz is defined as terminal elimination rate constant computed as the slope of the regression line of ln (C\[t\]) on time. The regression should generally involve at least 3 consecutive measurable concentrations that decrease over time. Blood samples were collected at the indicated time points for the analysis of λz. PK parameters were calculated by standard non-compartmental analysis.

    Time frame: Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)

  4. Time of the Maximum Observed Post-Dose Concentration (Tmax)

    Tmax is defined as the time of the maximum observed post-dose concentration. Blood samples were collected at the indicated time points for the analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.

    Time frame: Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)

  5. Elimination Half-Life (T1/2)

    T1/2 is defined as elimination half-life computed as T1/2 = ln(2)/ λz. Blood samples were collected at the indicated time points for the analysis of T1/2. PK parameters were calculated by standard non-compartmental analysis.

    Time frame: Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)

07

Results

Posted Feb 5, 2024

Participant flow

The study was conducted at single center in Canada.

Period 1 (2 Days)
Participant flow — Period 1 (2 Days)
MilestoneEsomeprazole CG (Test)/Esomeprazole AZ (Reference)Esomeprazole AZ (Reference)/Esomeprazole CG (Test)
Started2629
Completed2629
Not completed00
Washout Period (7 Days)
Participant flow — Washout Period (7 Days)
MilestoneEsomeprazole CG (Test)/Esomeprazole AZ (Reference)Esomeprazole AZ (Reference)/Esomeprazole CG (Test)
Started2629
Completed2222
Not completed47
Withdrew: Positive result for coronavirus (covid)-1913
Withdrew: Withdrawal by subject01
Withdrew: Non-compliance with study requirements33
Period 2 (2 Days)
Participant flow — Period 2 (2 Days)
MilestoneEsomeprazole CG (Test)/Esomeprazole AZ (Reference)Esomeprazole AZ (Reference)/Esomeprazole CG (Test)
Started2222
Completed2222
Not completed00

Outcome measures

PrimaryMaximum Observed Post Dose Concentration (Cmax)

Cmax is defined as maximum observed post-dose concentration; obtained without interpolation. Blood samples were collected at the indicated time points for the analysis of Cmax. Pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis.

Time frame:
Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)
Reported as:
Geometric mean · Nanograms per milliliter
Maximum Observed Post Dose Concentration (Cmax)
Nanograms per milliliterEsomeprazole CG (Test)Esomeprazole AZ (Reference)
Maximum Observed Post Dose Concentration (Cmax)483 ± 51.1514 ± 46.2
Statistical analysis
  • Esomeprazole CG (Test) vs Esomeprazole AZ (Reference) · Ratio of geometric least squares mean: 0.9531 · 90% CI 0.8510 to 1.0673
PrimaryArea Under the Plasma Concentration Versus Time Curve Calculated From Time 0 to the Last Measurable Sampling Time Point

AUC(0-t) is defined as area under the plasma concentration versus time curve calculated from time 0 to the last measurable sampling time point t, computed using the linear trapezoidal rule. Blood samples were collected at the indicated time points for the analysis of AUC0-t. PK parameters were calculated by standard non-compartmental analysis.

Time frame:
Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)
Reported as:
Geometric mean · Hour*nanograms per milliliter
Area Under the Plasma Concentration Versus Time Curve Calculated From Time 0 to the Last Measurable Sampling Time Point
Hour*nanograms per milliliterEsomeprazole CG (Test)Esomeprazole AZ (Reference)
Area Under the Plasma Concentration Versus Time Curve Calculated From Time 0 to the Last Measurable Sampling Time Point772.10 ± 74.0815.55 ± 68.6
Statistical analysis
  • Esomeprazole CG (Test) vs Esomeprazole AZ (Reference) · Ratio of geometric least squares mean: 0.9538 · 90% CI 0.8980 to 1.0132
SecondaryArea Under the Plasma Concentration Versus Time Curve Calculated From Time 0 to Infinity (AUC0-inf)

AUC(0-inf) is defined as area under the plasma concentration versus time curve calculated from time 0 to infinity. AUC0-inf is equal to (=) AUC0-t plus (+) concentration at the last measurable sampling time point \[C(t)\]/terminal elimination rate constant (λz). Blood samples were collected at the indicated time points for the analysis of AUC0-inf. PK parameters were calculated by standard non-compartmental analysis.

Time frame:
Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)
Reported as:
Geometric mean · Hour*nanograms per milliliter
Area Under the Plasma Concentration Versus Time Curve Calculated From Time 0 to Infinity (AUC0-inf)
Hour*nanograms per milliliterEsomeprazole CG (Test)Esomeprazole AZ (Reference)
Area Under the Plasma Concentration Versus Time Curve Calculated From Time 0 to Infinity (AUC0-inf)792.72 ± 73.5800.94 ± 68.8
SecondaryPercentage of AUC(0-inf) Obtained by Extrapolation (%AUCex)

%AUCex is defined as percentage of AUC(0-inf) obtained by extrapolation, calculated as (1-\[AUC{0-t}/AUC{0-inf}\]) ×100. Blood samples were collected at the indicated time points for the analysis of %AUCex. PK parameters were calculated by standard non-compartmental analysis.

Time frame:
Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)
Reported as:
Geometric mean · Percentage of AUC Extrapolated
Percentage of AUC(0-inf) Obtained by Extrapolation (%AUCex)
Percentage of AUC ExtrapolatedEsomeprazole CG (Test)Esomeprazole AZ (Reference)
Percentage of AUC(0-inf) Obtained by Extrapolation (%AUCex)0.34 ± 109.10.35 ± 74.6
SecondaryTerminal Elimination Rate Constant

λz is defined as terminal elimination rate constant computed as the slope of the regression line of ln (C\[t\]) on time. The regression should generally involve at least 3 consecutive measurable concentrations that decrease over time. Blood samples were collected at the indicated time points for the analysis of λz. PK parameters were calculated by standard non-compartmental analysis.

Time frame:
Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)
Reported as:
Median · 1 per hour
Terminal Elimination Rate Constant
1 per hourEsomeprazole CG (Test)Esomeprazole AZ (Reference)
Terminal Elimination Rate Constant0.8839 (0.3528 to 1.4328)0.8504 (0.3524 to 1.5184)
SecondaryTime of the Maximum Observed Post-Dose Concentration (Tmax)

Tmax is defined as the time of the maximum observed post-dose concentration. Blood samples were collected at the indicated time points for the analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.

Time frame:
Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)
Reported as:
Median · Hour
Time of the Maximum Observed Post-Dose Concentration (Tmax)
HourEsomeprazole CG (Test)Esomeprazole AZ (Reference)
Time of the Maximum Observed Post-Dose Concentration (Tmax)1.983 (0.733 to 5.983)1.983 (0.983 to 4.483)
SecondaryElimination Half-Life (T1/2)

T1/2 is defined as elimination half-life computed as T1/2 = ln(2)/ λz. Blood samples were collected at the indicated time points for the analysis of T1/2. PK parameters were calculated by standard non-compartmental analysis.

Time frame:
Pre-dose (within 1 hour prior to dosing), 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 12, 16, and 24 hours post dose in each treatment period (each period is of 2 days)
Reported as:
Median · Hour
Elimination Half-Life (T1/2)
HourEsomeprazole CG (Test)Esomeprazole AZ (Reference)
Elimination Half-Life (T1/2)0.78 (0.48 to 1.96)0.82 (0.46 to 1.97)

Adverse events

Collected over Adverse Events (AEs) were collected from the signing of informed consent until 5 days after last administration of study product (up to 41 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esomeprazole CG (Test)0/48 (0%)0/48 (0%)8/48 (16.7%)
Esomeprazole AZ (Reference)0/51 (0%)0/51 (0%)13/51 (25.5%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventEsomeprazole CG (Test)Esomeprazole AZ (Reference)
Covid-19Infections and infestations1/484/51
HeadacheNervous system disorders1/483/51
Urinary tract infectionInfections and infestations1/480/51
DizzinessNervous system disorders1/480/51
Red blood cells urineInvestigations1/481/51
Blood creatine phosphokinase increasedInvestigations1/480/51
Muscle spasmsMusculoskeletal and connective tissue disorders1/480/51
Decreased appetiteMetabolism and nutrition disorders1/480/51
InsomniaPsychiatric disorders1/480/51
DysmenorrhoeaReproductive system and breast disorders1/480/51

Baseline characteristics

Safety population- comprised all randomized participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Esomeprazole CG (Test)/Esomeprazole AZ (Reference)Esomeprazole AZ (Reference)/Esomeprazole CG (Test)Total
Mean39.4 ± 9.6337.0 ± 10.9038.1 ± 10.30
Sex: Female, Male
Sex: Female, Male(Participants)Esomeprazole CG (Test)/Esomeprazole AZ (Reference)Esomeprazole AZ (Reference)/Esomeprazole CG (Test)Total
Female182139
Male8816
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Esomeprazole CG (Test)/Esomeprazole AZ (Reference)Esomeprazole AZ (Reference)/Esomeprazole CG (Test)Total
Hispanic or Latino459
Not Hispanic or Latino222446
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Esomeprazole CG (Test)/Esomeprazole AZ (Reference)Esomeprazole AZ (Reference)/Esomeprazole CG (Test)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White252954
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Syneos health
    Québec, G1P0A2, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Jun 2022, 3 months.

Results were first posted in Feb 2024, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2022
First posted
Mar 3, 2022
StartActual
Mar 2, 2022
Primary completionActual
Jun 2, 2022
CompletionActual
Jun 2, 2022
Results first posted
Feb 5, 2024
Last update
Feb 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05265247
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Mar 3, 2022
Start date
Mar 2, 2022
Primary completion
Jun 2, 2022
Completion
Jun 2, 2022
Results posted
Feb 5, 2024
Last update
Feb 5, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion